comparemela.com

Latest Breaking News On - Severity index activity - Page 1 : comparemela.com

Afimetoran Shown to be Safe, Well-Tolerated for Patients with Cutaneous Lupus Erythematosus

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with cutaneous lupus erythematosus (CLE).

Jonathan Sadeh, MD, MSc: Afimetoran Improves Disease Activity, Severity in Lupus

Results provide the first clinical evidence to suggest that afimetoran may offer a benefit to patients with cutaneous lupus erythematosus.

Teen With Severe, Recalcitrant Dermatomyositis Seeks New Option

Afimetoran Shown to be Safe, Well-Tolerated for Patients with Cutaneous Lupus Erythematosus

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.